Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2019

01-10-2019 | Lymphoma | Guideline

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-2. Marginal zone lymphoma (MALT lymphoma/extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue and splenic marginal zone lymphoma)

Author: Yukio Kobayashi

Published in: International Journal of Hematology | Issue 4/2019

Login to get access

Excerpt

Marginal zone lymphoma is classified as extranodal marginal zone lymphoma, nodal marginal zone lymphoma, or splenic marginal zone lymphoma depending on the site of origin. Extranodal marginal zone lymphoma, part of the marginal zone lymphoma that originates outside of the lymph nodes, is synonymous with lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). MALT lymphoma, splenic marginal zone lymphoma that originates in the spleen, and nodal marginal zone lymphoma that originates in the lymph nodes, are the three entities in the category of marginal zone lymphoma. …
Metadata
Title
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-2. Marginal zone lymphoma (MALT lymphoma/extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue and splenic marginal zone lymphoma)
Author
Yukio Kobayashi
Publication date
01-10-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02719-6

Other articles of this Issue 4/2019

International Journal of Hematology 4/2019 Go to the issue

Original Article

Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis

Original Article

The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores

Case Report

Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation

Rapid Communication

CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma

Original Article

Molecular characteristics of thalassemia and hemoglobin variants in prenatal diagnosis program in northern Thailand

Case Report

Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits